Log in

TSE:BLUBELLUS Health Stock Price, Forecast & News

C$3.41
-0.18 (-5.01 %)
(As of 08/12/2020 05:14 AM ET)
Add
Compare
Today's Range
C$3.40
Now: C$3.41
C$3.60
50-Day Range
C$3.28
MA: C$7.52
C$16.38
52-Week Range
C$3.15
Now: C$3.41
C$16.68
Volume203,705 shs
Average Volume167,987 shs
Market CapitalizationC$205.45 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-450-6804500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$21,692.00
Cash FlowC$1.08 per share
Book ValueC$2.11 per share

Profitability

Miscellaneous

Employees10
Market CapC$205.45 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable
C$3.41
-0.18 (-5.01 %)
(As of 08/12/2020 05:14 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLU News and Ratings via Email

Sign-up to receive the latest news and ratings for BLU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BELLUS Health (TSE:BLU) Frequently Asked Questions

How has BELLUS Health's stock been impacted by COVID-19 (Coronavirus)?

BELLUS Health's stock was trading at C$13.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BLU stock has decreased by 73.8% and is now trading at C$3.41.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of BELLUS Health?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BELLUS Health
.

When is BELLUS Health's next earnings date?

BELLUS Health is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for BELLUS Health
.

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc (TSE:BLU) released its quarterly earnings data on Thursday, May, 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.01. The company earned $0.01 million during the quarter, compared to analyst estimates of $0.01 million.
View BELLUS Health's earnings history
.

Has BELLUS Health been receiving favorable news coverage?

News stories about BLU stock have trended negative this week, according to InfoTrie. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BELLUS Health earned a news impact score of -2.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about BELLUS Health
.

Who are some of BELLUS Health's key competitors?

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include AbbVie (ABBV), Energy Transfer LP Unit (ET), Maxar Technologies (MAXR), Wells Fargo & Co (WFC), Exxon Mobil (XOM), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Bank of America (BAC), BlackBerry (BB) and Emera (EMA).

Who are BELLUS Health's key executives?

BELLUS Health's management team includes the following people:
  • Mr. Roberto Bellini, Pres, CEO & Director (Age 39)
  • Mr. François Desjardins C.A., CPA, CPA, CA, VP of Fin. (Age 56)
  • Dr. Denis Garceau, Sr. VP of Drug Devel. (Age 62)
  • Mr. Tony Matzouranis, VP of Bus. Devel. (Age 46)
  • Mr. Sébastien Roy, Corp. Sec. (Age 43)

What is BELLUS Health's stock symbol?

BELLUS Health trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BLU."

How do I buy shares of BELLUS Health?

Shares of BLU and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is BELLUS Health's stock price today?

One share of BLU stock can currently be purchased for approximately C$3.41.

How big of a company is BELLUS Health?

BELLUS Health has a market capitalization of C$205.45 million and generates C$21,692.00 in revenue each year. BELLUS Health employs 10 workers across the globe.

What is BELLUS Health's official website?

The official website for BELLUS Health is www.bellushealth.com.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada. The company can be reached via phone at +1-450-6804500.

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.